Business
Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company de
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes","length":204,"tagName":"p"},{"type":"text","content":"Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease ","length":143,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study (PoC 1) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. The analysis evaluated patient-reported quality-of-life, symptom and functional outcomes as a secondary endpoint of the study using the EORTC QLQ-C30 scale (a validated measure of cancer-specific quality of life) across multiple patient subgroups, including tumor stage and metastatic status. Results from this post-hoc exploratory analysis suggested that Autonomix’s targeted ablation therapy may have produced improvements in symptom burden, functionality, and global quality of life following Autonomix’s targeted ablation therapy.","length":1070,"tagName":"p"},{"type":"text","content":"The analysis also provided new procedural findings that will be used to guide Autonomix’s U.S. clinical trial, which is on track to commence in 2026.","length":149,"tagName":"p"},{"type":"text","content":"Key Findings from the Subgroup Analysis:...